Publications by Elisabeth Gulowsen Celius
169 publications found
Original articles
"No association between disease modifying treatment and fatigue in multiple sclerosis"
Mult Scler Relat Disord, 79, 104993
DOI 10.1016/j.msard.2023.104993, PubMed 37708819
The instrumented single leg stance test detects early balance impairment in people with multiple sclerosis
Front Neurol, 14, 1227374
DOI 10.3389/fneur.2023.1227374, PubMed 37538255
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
JCI Insight, 8 (12)
DOI 10.1172/jci.insight.165111, PubMed 37159281
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults
Brain, 146 (6), 2489-2501
DOI 10.1093/brain/awac480, PubMed 36515653
Cancer related mortality in multiple sclerosis. A population based cohort study
Mult Scler Relat Disord, 69, 104417
DOI 10.1016/j.msard.2022.104417, PubMed 36423459
Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population
Front Neurol, 13, 1034056
DOI 10.3389/fneur.2022.1034056, PubMed 36452173
Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy
J Neurol, 269 (11), 5901-5909
DOI 10.1007/s00415-022-11249-x, PubMed 35780399
Fatigue in multiple sclerosis is associated with socioeconomic factors
Mult Scler Relat Disord, 64, 103955
DOI 10.1016/j.msard.2022.103955, PubMed 35753177
Exploring Retinal Blood Vessel Diameters as Biomarkers in Multiple Sclerosis
J Clin Med, 11 (11)
DOI 10.3390/jcm11113109, PubMed 35683496
Deep neural networks learn general and clinically relevant representations of the ageing brain
Neuroimage, 256, 119210
DOI 10.1016/j.neuroimage.2022.119210, PubMed 35462035
Association of adverse childhood experiences with the development of multiple sclerosis
J Neurol Neurosurg Psychiatry, 93 (6), 645-650
DOI 10.1136/jnnp-2021-328700, PubMed 35379699
The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort
Mult Scler Relat Disord, 61, 103759
DOI 10.1016/j.msard.2022.103759, PubMed 35358792
Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation
J Neurol, 269 (7), 3723-3734
DOI 10.1007/s00415-022-10998-z, PubMed 35166925
Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study
Mult Scler Relat Disord, 58, 103404
DOI 10.1016/j.msard.2021.103404, PubMed 35216786
Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists
Mult Scler Relat Disord, 57, 103389
DOI 10.1016/j.msard.2021.103389, PubMed 35158479
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
J Neurol Neurosurg Psychiatry, 94 (1), 19-22
DOI 10.1136/jnnp-2021-327612, PubMed 34670844
Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study
Mult Scler Relat Disord, 55, 103209
DOI 10.1016/j.msard.2021.103209, PubMed 34419754
No significant differences in absenteeism or academic achievements in a Norwegian multiple sclerosis case control study
Mult Scler Relat Disord, 54, 103141
DOI 10.1016/j.msard.2021.103141, PubMed 34273610
Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry
Front Neurol, 12, 693017
DOI 10.3389/fneur.2021.693017, PubMed 34220694
Maternal education has significant influence on progression in multiple sclerosis
Mult Scler Relat Disord, 53, 103052
DOI 10.1016/j.msard.2021.103052, PubMed 34111658
High prevalence of fatigue in contemporary patients with multiple sclerosis
Mult Scler J Exp Transl Clin, 7 (1), 2055217321999826
DOI 10.1177/2055217321999826, PubMed 33796331
Management of Severe Graves' Hyperthyroidism in Pregnancy Following Immune Reconstitution Therapy in Multiple Sclerosis
J Endocr Soc, 5 (6), bvab044
DOI 10.1210/jendso/bvab044, PubMed 34017934
CD8+ T cell gene expression analysis identifies differentially expressed genes between multiple sclerosis patients and healthy controls
Mult Scler J Exp Transl Clin, 6 (4), 2055217320978511
DOI 10.1177/2055217320978511, PubMed 33343920
The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression
J Neurol, 268 (4), 1330-1341
DOI 10.1007/s00415-020-10279-7, PubMed 33090270
The genetic architecture of human brainstem structures and their involvement in common brain disorders
Nat Commun, 11 (1), 4016
DOI 10.1038/s41467-020-17376-1, PubMed 32782260
Prevalence of multiple sclerosis in rural and urban districts in Telemark county, Norway
Mult Scler Relat Disord, 45, 102352
DOI 10.1016/j.msard.2020.102352, PubMed 32707528
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies
Neurol Ther, 9 (2), 443-457
DOI 10.1007/s40120-020-00191-7, PubMed 32410147
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years
Mult Scler Relat Disord, 43, 102146
DOI 10.1016/j.msard.2020.102146, PubMed 32498033
The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis
Mult Scler J Exp Transl Clin, 6 (1), 2055217319901291
DOI 10.1177/2055217319901291, PubMed 32030196
Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study
Mult Scler, 26 (12), 1569-1580
DOI 10.1177/1352458519877244, PubMed 31573834
Common brain disorders are associated with heritable patterns of apparent aging of the brain
Nat Neurosci, 22 (10), 1617-1623
DOI 10.1038/s41593-019-0471-7, PubMed 31551603
No differential gene expression for CD4+ T cells of MS patients and healthy controls
Mult Scler J Exp Transl Clin, 5 (2), 2055217319856903
DOI 10.1177/2055217319856903, PubMed 31223483
Neurodegenerative Interplay of Cardiovascular Autonomic Dysregulation and the Retina in Early Multiple Sclerosis
Front Neurol, 10, 507
DOI 10.3389/fneur.2019.00507, PubMed 31156539
International consensus on quality standards for brain health-focused care in multiple sclerosis
Mult Scler, 25 (13), 1809-1818
DOI 10.1177/1352458518809326, PubMed 30381987
Increased DNA methylation of SLFN12 in CD4+ and CD8+ T cells from multiple sclerosis patients
PLoS One, 13 (10), e0206511
DOI 10.1371/journal.pone.0206511, PubMed 30379917
[Teaching has low academic status]
Tidsskr Nor Laegeforen, 138 (12)
DOI 10.4045/tidsskr.18.0341, PubMed 30132612
DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis
Nat Commun, 9 (1), 2397
DOI 10.1038/s41467-018-04732-5, PubMed 29921915
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity
Brain Behav, 8 (5), e00962
DOI 10.1002/brb3.962, PubMed 29761015
Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis
Mult Scler, 25 (5), 687-698
DOI 10.1177/1352458518765671, PubMed 29542336
Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations
NPJ Genom Med, 2, 24
DOI 10.1038/s41525-017-0027-2, PubMed 29263835
Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis
Neuroradiology, 59 (7), 655-664
DOI 10.1007/s00234-017-1849-4, PubMed 28585082
Fatigue and cognition: Pupillary responses to problem-solving in early multiple sclerosis patients
Brain Behav, 7 (7), e00717
DOI 10.1002/brb3.717, PubMed 28729927
Migraine and frequent tension-type headache are not associated with multiple sclerosis in a Norwegian case-control study
Mult Scler J Exp Transl Clin, 2, 2055217316682976
DOI 10.1177/2055217316682976, PubMed 28607748
Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
BMC Neurol, 16 (1), 252
DOI 10.1186/s12883-016-0771-4, PubMed 27919248
[MRI in multiple sclerosis]
Tidsskr Nor Laegeforen, 136 (16), 1373-6
DOI 10.4045/tidsskr.15.1361, PubMed 27637059
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies
Neurol Genet, 2 (4), e87
DOI 10.1212/NXG.0000000000000087, PubMed 27540591
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies
Neurol.-Genet., 2 (4), eB7
DOI 10.1212/NXG.00000000000000B7
Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study
Mult Scler, 23 (2), 213-219
DOI 10.1177/1352458516646863, PubMed 27207453
High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud
Acta Neurol Scand, 135 (4), 412-418
DOI 10.1111/ane.12615, PubMed 27241360
The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells
Genes Immun, 17 (2), 118-27
DOI 10.1038/gene.2015.61, PubMed 26765264
Reduced perfusion in white matter lesions in multiple sclerosis
Eur J Radiol, 84 (12), 2605-12
DOI 10.1016/j.ejrad.2015.09.007, PubMed 26391230
Class II HLA interactions modulate genetic risk for multiple sclerosis
Nat Genet, 47 (10), 1107-1113
DOI 10.1038/ng.3395, PubMed 26343388
A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity
PLoS One, 10 (8), e0135974
DOI 10.1371/journal.pone.0135974, PubMed 26280173
Eye and hand motor interactions with the Symbol Digit Modalities Test in early multiple sclerosis
Mult Scler Relat Disord, 4 (6), 585-9
DOI 10.1016/j.msard.2015.08.003, PubMed 26590666
Multiple Sclerosis Risk Allele in CLEC16A Acts as an Expression Quantitative Trait Locus for CLEC16A and SOCS1 in CD4+ T Cells
PLoS One, 10 (7), e0132957
DOI 10.1371/journal.pone.0132957, PubMed 26203907
Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness
Front Neurol, 6, 18
DOI 10.3389/fneur.2015.00018, PubMed 25755648
Genetic variants are major determinants of CSF antibody levels in multiple sclerosis
Brain, 138 (Pt 3), 632-43
DOI 10.1093/brain/awu405, PubMed 25616667
Prevalence of multiple sclerosis among immigrants in Norway
Mult Scler, 21 (6), 695-702
DOI 10.1177/1352458514554055, PubMed 25344371
Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study
BMC Neurol, 14, 196
DOI 10.1186/s12883-014-0196-x, PubMed 25274070
Multiple sclerosis and seizures: incidence and prevalence over 40 years
Acta Neurol Scand, 130 (6), 368-73
DOI 10.1111/ane.12276, PubMed 25209977
Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort
Eur J Hum Genet, 23 (5), 688-92
DOI 10.1038/ejhg.2014.155, PubMed 25159868
Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis
Mult Scler, 21 (4), 402-14
DOI 10.1177/1352458514543811, PubMed 25139946
No association between multiple sclerosis and periodontitis after adjusting for smoking habits
Eur J Neurol, 22 (3), 588-90
DOI 10.1111/ene.12520, PubMed 25041906
Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general
J Neuroimmunol, 274 (1-2), 174-9
DOI 10.1016/j.jneuroim.2014.06.024, PubMed 25037176
High prevalence and no latitude gradient of multiple sclerosis in Norway
Mult Scler, 20 (13), 1780-2
DOI 10.1177/1352458514525871, PubMed 24603884
Month of birth and risk of multiple sclerosis: confounding and adjustments
Ann Clin Transl Neurol, 1 (2), 141-4
DOI 10.1002/acn3.37, PubMed 25356394
Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights
Eur Neurol, 72 Suppl 1, 15-9
DOI 10.1159/000367619, PubMed 25278119
Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis
Mult Scler, 20 (6), 660-8
DOI 10.1177/1352458513506503, PubMed 24099750
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Nat Genet, 45 (11), 1353-60
DOI 10.1038/ng.2770, PubMed 24076602
Increased disease severity in non-Western immigrants with multiple sclerosis in Oslo, Norway
Eur J Neurol, 20 (12), 1546-52
DOI 10.1111/ene.12227, PubMed 23834430
No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis
Ann Neurol, 73 (3), 430-2
DOI 10.1002/ana.23833, PubMed 23444327
Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway
J Neurol, 260 (6), 1481-8
DOI 10.1007/s00415-012-6814-x, PubMed 23292231
Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles
PLoS One, 8 (3), e58352
DOI 10.1371/journal.pone.0058352, PubMed 23472185
Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting
PLoS One, 8 (3), e58643
DOI 10.1371/journal.pone.0058643, PubMed 23555589
Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients
PLoS One, 8 (6), e64408
DOI 10.1371/journal.pone.0064408, PubMed 23785401
Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway
Mult Scler, 19 (8), 1028-34
DOI 10.1177/1352458512471094, PubMed 23257620
Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans
Neurosci Lett, 530 (2), 155-60
DOI 10.1016/j.neulet.2012.10.008, PubMed 23069673
Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course
J Neuroimmunol, 244 (1-2), 107-10
DOI 10.1016/j.jneuroim.2012.01.011, PubMed 22341604
Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis
PLoS One, 7 (5), e36779
DOI 10.1371/journal.pone.0036779, PubMed 22586495
Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study
PLoS One, 7 (9), e45703
DOI 10.1371/journal.pone.0045703, PubMed 23029191
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Nature, 476 (7359), 214-9
DOI 10.1038/nature10251, PubMed 21833088
No influence on disease progression of non-HLA susceptibility genes in MS
J Neuroimmunol, 237 (1-2), 98-100
DOI 10.1016/j.jneuroim.2011.05.003, PubMed 21742385
Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome
Neurology, 77 (2), 151-7
DOI 10.1212/WNL.0b013e3182242d34, PubMed 21747073
Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655
Eur J Hum Genet, 19 (10), 1100-3
DOI 10.1038/ejhg.2011.88, PubMed 21610746
[Treatment of stroke--an interdisciplinary challenge]
Tidsskr Nor Laegeforen, 131 (9-10), 934-6
DOI 10.4045/tidsskr.11.0424, PubMed 21606987
Fractures and falls in patients with newly diagnosed clinically isolated syndrome and multiple sclerosis
Acta Neurol Scand Suppl (191), 79-82
DOI 10.1111/j.1600-0404.2011.01548.x, PubMed 21711261
Genetic association of multiple sclerosis with the marker rs391745 near the endogenous retroviral locus HERV-Fc1: analysis of disease subtypes
PLoS One, 6 (10), e26438
DOI 10.1371/journal.pone.0026438, PubMed 22039488
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus
Genes Immun, 12 (3), 191-8
DOI 10.1038/gene.2010.59, PubMed 21179112
IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation
J Immunol, 185 (11), 6883-90
DOI 10.4049/jimmunol.1001392, PubMed 21041731
Association to the Glypican-5 gene in multiple sclerosis
J Neuroimmunol, 226 (1-2), 194-7
DOI 10.1016/j.jneuroim.2010.07.003, PubMed 20692050
Two HLA class I genes independently associated with multiple sclerosis
J Neuroimmunol, 226 (1-2), 172-6
DOI 10.1016/j.jneuroim.2010.07.006, PubMed 20678810
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial
Lancet Neurol, 9 (7), 672-80
DOI 10.1016/S1474-4422(10)70132-0, PubMed 20542736
Cognitive impairment after three decades of multiple sclerosis
Eur J Neurol, 17 (3), 499-505
DOI 10.1111/j.1468-1331.2009.02889.x, PubMed 20050887
A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis
Eur J Hum Genet, 18 (4), 502-4
DOI 10.1038/ejhg.2009.195, PubMed 19888296
Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis
Genes Immun, 11 (2), 142-54
DOI 10.1038/gene.2009.82, PubMed 19865101
Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients
Mult Scler, 15 (11), 1263-70
DOI 10.1177/1352458509107010, PubMed 19812114
Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis
Ann Neurol, 65 (6), 658-66
DOI 10.1002/ana.21695, PubMed 19630074
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor
Eur J Hum Genet, 17 (10), 1309-13
DOI 10.1038/ejhg.2009.41, PubMed 19293837
MYO9B polymorphisms in multiple sclerosis
Eur J Hum Genet, 17 (6), 840-3
DOI 10.1038/ejhg.2008.251, PubMed 19142207
Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades
Acta Neurol Scand Suppl (189), 27-9
DOI 10.1111/j.1600-0404.2009.01208.x, PubMed 19566494
Perceptions of illness and its development in patients with multiple sclerosis: a prospective cohort study
J Adv Nurs, 65 (1), 184-92
DOI 10.1111/j.1365-2648.2008.04862.x, PubMed 19032506
The SH2D2A gene and susceptibility to multiple sclerosis
J Neuroimmunol, 197 (2), 152-8
DOI 10.1016/j.jneuroim.2008.04.037, PubMed 18554728
Cost-effectiveness of natalizumab in multiple sclerosis
Expert Rev Pharmacoecon Outcomes Res, 8 (1), 11-21
DOI 10.1586/14737167.8.1.11, PubMed 20528351
Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway
J Neurol, 255 (1), 49-55
DOI 10.1007/s00415-007-0659-8, PubMed 18080855
X chromosome inactivation in females with multiple sclerosis
Eur J Neurol, 14 (12), 1392-6
DOI 10.1111/j.1468-1331.2007.01987.x, PubMed 17970735
A prospective study of patterns of fatigue in multiple sclerosis
Eur J Neurol, 14 (12), 1338-43
DOI 10.1111/j.1468-1331.2007.01974.x, PubMed 17903208
[A rush job and knowledge handling]
Tidsskr Nor Laegeforen, 127 (15), 1961-2
PubMed 17700745
The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients
Eur J Neurol, 14 (8), 835-40
DOI 10.1111/j.1468-1331.2007.01825.x, PubMed 17662002
Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis
Nat Genet, 39 (9), 1108-13
DOI 10.1038/ng2106, PubMed 17660816
Low frequency of the disease-associated DRB1*15-DQB1*06 haplotype may contribute to the low prevalence of multiple sclerosis in Sami
Tissue Antigens, 69 (4), 299-304
DOI 10.1111/j.1399-0039.2007.00803.x, PubMed 17389012
A follow-up study of Nordic multiple sclerosis candidate gene regions
Mult Scler, 13 (5), 584-9
DOI 10.1177/1352458506071790, PubMed 17548436
Familial effects on the clinical course of multiple sclerosis
Neurology, 68 (5), 376-83
DOI 10.1212/01.wnl.0000252822.53506.46, PubMed 17261686
Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations
J Neuroimmunol, 180 (1-2), 193-8
DOI 10.1016/j.jneuroim.2006.08.009, PubMed 17020785
Coding region polymorphisms in T cell signal transduction genes. Prevalence and association to development of multiple sclerosis
J Neuroimmunol, 177 (1-2), 40-5
DOI 10.1016/j.jneuroim.2006.04.021, PubMed 16764945
Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients
J Neuroimmunol, 166 (1-2), 197-201
DOI 10.1016/j.jneuroim.2005.06.002, PubMed 16005527
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
Neurology, 64 (7), 1144-51
DOI 10.1212/01.WNL.0000156155.19270.F8, PubMed 15824338
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis
Tissue Antigens, 63 (3), 237-47
DOI 10.1111/j.0001-2815.2004.00173.x, PubMed 14989713
Depressive symptoms account for deficient information processing speed but not for impaired working memory in early phase multiple sclerosis (MS)
J Neurol Sci, 217 (2), 211-6
DOI 10.1016/j.jns.2003.10.012, PubMed 14706226
Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs
Mult Scler, 10 (1), 5-8
DOI 10.1191/1352458504ms975oa, PubMed 14760946
Fatigue and its association with sociodemographic variables among multiple sclerosis patients
Mult Scler, 9 (5), 509-14
DOI 10.1191/1352458503ms943oa, PubMed 14582778
Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients
J Neuroimmunol, 143 (1-2), 101-6
DOI 10.1016/j.jneuroim.2003.08.021, PubMed 14575924
Radon: a possible risk factor in multiple sclerosis
Neuroepidemiology, 22 (1), 87-94
DOI 10.1159/000067102, PubMed 12566959
Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period
Eur J Neurol, 8 (5), 463-9
DOI 10.1046/j.1468-1331.2001.00269.x, PubMed 11554910
The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis
Genes Immun, 2 (5), 263-8
DOI 10.1038/sj.gene.6363774, PubMed 11528519
Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis
J Neurol Sci, 178 (2), 132-5
DOI 10.1016/s0022-510x(00)00389-0, PubMed 11018705
Memory functioning and emotional changes in early phase multiple sclerosis
Arch Clin Neuropsychol, 15 (1), 37-46
DOI 10.1016/S0887-6177(98)00151-6, PubMed 14590566
Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis
Neurology, 52 (5), 1049-56
DOI 10.1212/wnl.52.5.1049, PubMed 10102427
CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis
Tissue Antigens, 53 (1), 106-10
DOI 10.1034/j.1399-0039.1999.530112.x, PubMed 10082437
[Differences in morbidity between the Eastern central city district and the suburban Western district of Oslo]
Tidsskr Nor Laegeforen, 118 (1), 14-7
PubMed 9481903
The HLA-DQ(alpha 1*0102, beta 1*0602) heterodimer may confer susceptibility to multiple sclerosis in the absence of the HLA-DR(alpha 1*01, beta 1*1501) heterodimer
Tissue Antigens, 50 (1), 15-22
DOI 10.1111/j.1399-0039.1997.tb02828.x, PubMed 9243750
[Neurologic complications in heroin abuse. Illustrated by two unusual cases]
Tidsskr Nor Laegeforen, 117 (3), 356-7
PubMed 9064856
Review articles
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
Mult Scler Relat Disord, 69, 104459
DOI 10.1016/j.msard.2022.104459, PubMed 36565573
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives
Patient Prefer Adherence, 15, 15-27
DOI 10.2147/PPA.S268829, PubMed 33447018
Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways
Mult Scler Relat Disord, 46, 102533
DOI 10.1016/j.msard.2020.102533, PubMed 33010585
State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis
Neurol Ther, 9 (2), 281-300
DOI 10.1007/s40120-020-00202-7, PubMed 32666470
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings
Front Neurol, 10, 253
DOI 10.3389/fneur.2019.00253, PubMed 30967831
Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
Acta Neurol Scand, 136 Suppl 201, 34-36
DOI 10.1111/ane.12835, PubMed 29068490
Is the hygiene hypothesis relevant for the risk of multiple sclerosis?
Acta Neurol Scand, 136 Suppl 201, 26-30
DOI 10.1111/ane.12844, PubMed 29068485
From genetic associations to functional studies in multiple sclerosis
Eur J Neurol, 23 (5), 847-53
DOI 10.1111/ene.12981, PubMed 26948534
Socio-economic factors and immigrant population studies of multiple sclerosis
Acta Neurol Scand, 132 (199), 37-41
DOI 10.1111/ane.12429, PubMed 26046557
[New gene map for multiple sclerosis]
Tidsskr Nor Laegeforen, 131 (21), 2126-30
DOI 10.4045/tidsskr.10.0823, PubMed 22048209
[Development of new therapies for multiple sclerosis]
Tidsskr Nor Laegeforen, 131 (8), 832-6
DOI 10.4045/tidsskr.10.0077, PubMed 21556088
[New diagnostic criteria in multiple sclerosis]
Tidsskr Nor Laegeforen, 123 (10), 1345-8
PubMed 12806674
Other articles
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
Mult Scler Relat Disord, 62, 103812
DOI 10.1016/j.msard.2022.103812, PubMed 35462167
Normal antibody response after COVID-19 during treatment with cladribine
Mult Scler Relat Disord, 46, 102476
DOI 10.1016/j.msard.2020.102476, PubMed 32882501
Breastfeeding and treatment of multiple sclerosis
Mult Scler, 27 (5), 801-802
DOI 10.1177/1352458520931786, PubMed 32507035
Publisher Correction: Common brain disorders are associated with heritable patterns of apparent aging of the brain
Nat Neurosci, 23 (2), 295
DOI 10.1038/s41593-019-0553-6, PubMed 31848485
Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease
J Neurol, 266 (5), 1270-1271
DOI 10.1007/s00415-019-09257-5, PubMed 30805797
Teaching has a low status within academia
Tidsskr. Nor. Laegeforen., 138 (12), 1155
Preface
Acta Neurol Scand, 136 Suppl 201, 3
DOI 10.1111/ane.12842, PubMed 29068489
[Not Available]
Tidsskr Nor Laegeforen, 136 (20), 1702
DOI 10.4045/tidsskr.16.0865, PubMed 27830899
[Not Available]
Tidsskr Nor Laegeforen, 136 (19), 1608
DOI 10.4045/tidsskr.16.0826, PubMed 27790879
MRI- investigations in multiple sclerosis
Tidsskr. Nor. Laegeforen., 136 (16), 1373-1376
Preface
Acta Neurol Scand, 134 Suppl 200, 3
DOI 10.1111/ane.12653, PubMed 27580898
Comments on the review article 'Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades'
Acta Neurol Scand, 132 (5), 364-7
DOI 10.1111/ane.12489, PubMed 26423981
Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments
Ann Clin Transl Neurol, 1 (5), 376-7
DOI 10.1002/acn3.56, PubMed 25356407
Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis
Nat Genet, 42 (6), 469-70; author reply 470-1
DOI 10.1038/ng0610-469, PubMed 20502484
[Treatment of multiple sclerosis]
Tidsskr Nor Laegeforen, 130 (9), 923; author reply 923
DOI 10.4045/tidsskr.10.0346, PubMed 20453948
[Incorrect information about treatment of multiple sclerosis from the Knowledge Center]
Tidsskr Nor Laegeforen, 127 (12), 1672-3; author reply 1673
PubMed 17571115
[Retraction of article]
Tidsskr Nor Laegeforen, 125 (15), 2056
PubMed 16208878
[Optic neuritis--diagnosis, treatment and follow up]
Tidsskr Nor Laegeforen, 125 (4), 425-8 (Retracted)
PubMed 15742012
Leucoencephalopathy after inhalation of heroin: a case report
J Neurol Neurosurg Psychiatry, 60 (6), 694-5
DOI 10.1136/jnnp.60.6.694, PubMed 8648344
Books
Hva er MS?
Biogen Idec, Oslo (Oppdatert juni 2004), 38 s.
BIBSYS 061633496
Psykologi og MS
Biogen Idec, Oslo (Oppdatert juni 2004), 38 s.
BIBSYS 06163350x
Å leve med MS
Biogen IDEC Norge, Oslo, 31 s.
BIBSYS 041575970
Psykologi og MS
Ariez Pharma Consultancy, Amsterdam, 38 s.
BIBSYS 020852878
Å leve med MS
Biogen, Amsterdam], 28 s.
BIBSYS 020853440
Hva er MS?
Ariez Pharma Consultancy, Amsterdam, 38 s.
BIBSYS 011580623
Book chapters
Multippel sklerose: er det sykdommen som skal styre livet?
In Pasienten og sykdommen: psykiske faktorer ved somatisk sykdom, Gyldendal akademisk, Oslo, S. 135-141
BIBSYS 071388192